State Board of Administration of Florida Retirement System Sells 6,020 Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR)

State Board of Administration of Florida Retirement System lowered its position in shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR – Get Rating) by 32.3% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 12,645 shares of the company’s stock after selling 6,020 shares during the quarter. State Board of Administration of Florida Retirement System’s holdings in Kymera Therapeutics were worth $316,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently modified their holdings of the stock. Price T Rowe Associates Inc. MD increased its holdings in shares of Kymera Therapeutics by 34.1% in the second quarter. Price T Rowe Associates Inc. MD now owns 5,224,686 shares of the company’s stock worth $102,874,000 after purchasing an additional 1,329,481 shares during the period. BVF Inc. IL increased its holdings in shares of Kymera Therapeutics by 13.4% in the third quarter. BVF Inc. IL now owns 4,692,604 shares of the company’s stock worth $102,158,000 after purchasing an additional 553,846 shares during the period. State Street Corp increased its holdings in shares of Kymera Therapeutics by 67.8% in the second quarter. State Street Corp now owns 3,514,438 shares of the company’s stock worth $69,199,000 after purchasing an additional 1,419,877 shares during the period. BlackRock Inc. increased its holdings in shares of Kymera Therapeutics by 0.6% in the first quarter. BlackRock Inc. now owns 3,419,084 shares of the company’s stock worth $144,698,000 after purchasing an additional 21,544 shares during the period. Finally, Wellington Management Group LLP increased its holdings in shares of Kymera Therapeutics by 19.7% in the first quarter. Wellington Management Group LLP now owns 3,225,749 shares of the company’s stock worth $136,514,000 after purchasing an additional 530,935 shares during the period.

Wall Street Analysts Forecast Growth

KYMR has been the subject of several research reports. Credit Suisse Group upped their target price on shares of Kymera Therapeutics from $32.00 to $39.00 and gave the stock a “neutral” rating in a research report on Friday, February 24th. HC Wainwright reiterated a “buy” rating and issued a $85.00 target price on shares of Kymera Therapeutics in a research report on Friday, February 24th. Finally, Raymond James upgraded shares of Kymera Therapeutics from a “market perform” rating to an “outperform” rating in a research report on Thursday, May 4th. Three analysts have rated the stock with a hold rating and six have given a buy rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $47.22.

Insider Activity at Kymera Therapeutics

In related news, CFO Bruce N. Jacobs sold 1,370 shares of the firm’s stock in a transaction that occurred on Thursday, March 2nd. The shares were sold at an average price of $31.00, for a total value of $42,470.00. Following the sale, the chief financial officer now owns 104,568 shares in the company, valued at $3,241,608. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 17.01% of the stock is owned by insiders.

Kymera Therapeutics Price Performance

KYMR stock opened at $29.65 on Monday. Kymera Therapeutics, Inc. has a 1 year low of $13.15 and a 1 year high of $39.85. The company has a market cap of $1.64 billion, a P/E ratio of -10.33 and a beta of 1.71. The firm has a 50-day moving average of $30.61 and a 200 day moving average of $30.65.

Kymera Therapeutics (NASDAQ:KYMR – Get Rating) last announced its earnings results on Thursday, May 4th. The company reported ($0.70) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.69) by ($0.01). The business had revenue of $9.47 million for the quarter, compared to the consensus estimate of $14.15 million. Kymera Therapeutics had a negative net margin of 340.80% and a negative return on equity of 34.15%. Kymera Therapeutics’s revenue for the quarter was down 1.6% on a year-over-year basis. During the same period in the prior year, the business posted ($0.71) EPS. On average, equities research analysts expect that Kymera Therapeutics, Inc. will post -2.66 earnings per share for the current fiscal year.

Kymera Therapeutics Profile

(Get Rating)

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.